L. Indications-des-inhibiteurs-du-fonctionnement-plaquettaire....... and .. Insuffisance-coronaire, 63 a), p.63

L. Situations-documentées-et-non-validées, .. De-risque-cardiovasculaire, .. De-lyme, and .. , 121 b) Extrasystoles supraventriculaires 122 c) Bloc de branche gauche 122 d) Pathologies valvulaires aortiques 123 e) Neuropathie optique ischémique 124 f) cardiopathie dilatée chez un patient aux antécédents de maladie 124 g) Pathologie thromboembolique veineuse 124 h) Anévrysme du septum interventriculaire, p.126

D. Lenoir, Assurance maladie. Bon usage du médicament : clopidogrel

T. Lecompte, Inhibiteurs du fonctionnement plaquettaire, EMC - H??matologie, vol.2, issue.1, pp.35-51, 2005.
DOI : 10.1016/j.emch.2004.12.001

P. Albaladejo, Aspirin Withdrawal and Acute Lower Limb Ischemia, Anesthesia & Analgesia, vol.99, issue.2, pp.440-443, 2004.
DOI : 10.1213/01.ANE.0000131965.61686.BD

J. P. Collet, Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes, Circulation, issue.16, pp.110-2361, 2004.

I. Sibon and J. M. Orgogozo, Antiplatelet drug discontinuation is a risk factor for ischemic stroke, Neurology, vol.62, issue.7, pp.1187-1196, 2004.
DOI : 10.1212/01.WNL.0000118288.04483.02

P. Albaladejo, Gestion du traitement antiplaquettaire oral chez les patients porteurs d'endoproth??ses coronaires, Annales Fran??aises d'Anesth??sie et de R??animation, vol.25, issue.7, pp.796-804, 2006.
DOI : 10.1016/j.annfar.2006.04.003

W. Burger, Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis, Journal of Internal Medicine, vol.35, issue.5, pp.399-414, 2005.
DOI : 10.1046/j.1464-410X.1996.19313.x

. Sfar, Agents antiplaquettaires et période périopératoire. Conférence d'experts, 2001.

. Sfar, Gestion du traitement antiplaquettaire oral chez les patients porteurs d'endoprothèses coronaires. Propositions du groupe d'experts, 2006.

B. Napoléon, La prise en charge des patients sous anticoagulants ou sous agents antiplaquettaires avant une endoscopie digestive, 2005.

J. Mantz and C. M. Samama, Essai national STRATAGEM??: la??mobilisation de??tous est indispensable??!, Annales Fran??aises d'Anesth??sie et de R??animation, vol.25, issue.2, pp.133-137, 2006.
DOI : 10.1016/j.annfar.2005.11.018

H. C. Stary, A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.14, issue.5, pp.840-56, 1994.
DOI : 10.1161/01.ATV.14.5.840

H. C. Stary, A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, Arterioscler Thromb Vasc Biol, issue.9, pp.15-1512, 1995.

A. Tedgui and Z. Mallat, [Atherosclerotic plaque formation], Rev Prat, vol.49, pp.2081-2087, 1999.

A. D. Lopez, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, The Lancet, vol.367, issue.9524, pp.367-1747, 2006.
DOI : 10.1016/S0140-6736(06)68770-9

E. Touze, [Prevalence of asymptomatic atherothrombotic lesions and risk of vascular events in patients with a stroke]. Arch Mal Coeur Vaiss, pp.15-30, 2005.

J. P. Levy, Physiologie de l'hémostase primaire Hématologie et transfusion ; collection Abrégés Masson, pp.297-300, 2001.

V. L. Serebruany, Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials, The American Journal of Cardiology, vol.95, issue.10, pp.95-1218, 2005.
DOI : 10.1016/j.amjcard.2005.01.049

C. Patrono, Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects, Chest, vol.126, issue.3, pp.234-264, 2004.
DOI : 10.1378/chest.126.3_suppl.234S

C. L. Campbell, Aspirin Dose for the Prevention of Cardiovascular Disease, JAMA, vol.297, issue.18, pp.2018-2042, 2007.
DOI : 10.1001/jama.297.18.2018

C. Patrono, Aspirin resistance: definition, mechanisms and clinical read-outs, Journal of Thrombosis and Haemostasis, vol.73, issue.8, pp.1710-1713, 2003.
DOI : 10.1067/mcp.2003.1

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1538-7836.2003.00284.x/pdf

J. L. Reny, [The concept of aspirin "resistance": mechanisms and clinical relevance], Rev Med Interne, issue.12, pp.30-1020, 2009.

S. H. Little and D. R. , Antiplatelet and anticoagulation for patients with prosthetic heart valves, Cochrane Database Syst Rev, vol.37, issue.2, p.3464, 2003.
DOI : 10.1016/S0735-1097(00)01135-9

D. Schryver, E. L. , A. Algra, and J. Van-gijn, Dipyridamole for preventing stroke and other vascular events in patients with vascular disease, Cochrane Database Syst Rev, issue.3, p.1820, 2007.

P. H. Halkes, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial, Lancet, issue.9523, pp.367-1665, 2006.

R. L. Sacco, Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke, New England Journal of Medicine, vol.359, issue.12, pp.359-1238, 2008.
DOI : 10.1056/NEJMoa0805002

URL : https://hal.archives-ouvertes.fr/hal-00627279

H. C. Diener, Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study, The Lancet Neurology, vol.7, issue.10, pp.875-84, 2008.
DOI : 10.1016/S1474-4422(08)70198-4

R. M. Guthrie, Review of ESPS-2: Prevention of Secondary Stroke and Transient Ischemic Attack Using Aspirin and Extended-Release Dipyridamole, Postgraduate Medicine, vol.48, issue.5, pp.203-208, 2009.
DOI : 10.1046/j.1365-2125.1999.00072.x

J. R. Vane and T. W. Meade, Second European Stroke Prevention Study (ESPS 2): clinical and pharmacological implications, J Neurol Sci, vol.145, issue.2, pp.123-128, 1997.

J. Desmeules, Clopidogrel et inhibiteurs de la pompe à protons : danger d'intéractions? Pharma-Flash, pp.9-12, 2009.

T. Simon, Genetic Determinants of Response to Clopidogrel and Cardiovascular Events, New England Journal of Medicine, vol.360, issue.4, pp.363-75, 2009.
DOI : 10.1056/NEJMoa0808227

J. L. Mega, Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine, vol.360, issue.4, pp.354-62, 2009.
DOI : 10.1056/NEJMoa0809171

URL : https://doi.org/10.1016/j.jvs.2009.02.023

O. Donoghue and M. L. , Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials, Lancet, issue.9694, pp.374-989, 2009.

R. J. Peters, Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, pp.108-1682, 2003.

S. R. Mehta, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, issue.9281, pp.358-527, 2001.

J. Berg, Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials, Clin Ther, issue.6, pp.29-1184, 2007.

C. M. Gibson, Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy???Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study, American Heart Journal, vol.155, issue.1, pp.133-142, 2008.
DOI : 10.1016/j.ahj.2007.08.034

L. Wallentin, P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use, Eur Heart J, issue.16, pp.30-1964, 2009.

S. D. Wiviott, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, vol.357, issue.20, pp.2001-2016, 2007.
DOI : 10.1056/NEJMoa0706482

Y. B. Pride, Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)???Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy, American Heart Journal, vol.158, issue.3, pp.158-179, 2009.
DOI : 10.1016/j.ahj.2009.06.021

P. A. Gurbel, Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study, Circulation, vol.121, issue.10, pp.1188-99
DOI : 10.1161/CIRCULATIONAHA.109.919456

L. Wallentin, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, vol.361, issue.11, pp.361-1045, 2009.
DOI : 10.1056/NEJMoa0904327

T. J. Verbeuren, [Terutroban and endothelial TP receptors in atherogenesis, Med Sci, vol.22, issue.4, pp.437-480, 2006.

H. Tunstall-pedoe, Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10- year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease, Lancet, issue.9164, pp.353-1547, 1999.

O. Hanon, [Coronary artery disease in patient 80 years and older], Rev Prat, vol.58, issue.14, pp.1565-70, 2008.

N. Danchin, [Epidemiology of acute coronary syndromes in France and in Europe, Ann Cardiol Angeiol, pp.37-41

F. Delahaye, Prise en charge de l'infarctus du myocarde après la phase aiguë, Arch Mal Coeur Vaiss, 2001.

C. Patrono, Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology, European Heart Journal, vol.25, issue.2, pp.166-81, 2004.
DOI : 10.1016/j.ehj.2003.10.013

S. C. Smith and . Jr, AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute, Circulation, vol.113, issue.19, pp.47-2130, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.174516

R. A. Harrington, Antithrombotic Therapy for Coronary Artery Disease, Chest, vol.126, issue.3, pp.513-548, 2004.
DOI : 10.1378/chest.126.3_suppl.513S

M. E. Bertrand, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal, vol.23, issue.23, pp.1809-1849, 2002.
DOI : 10.1053/euhj.2002.3385

S. Yusuf, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, issue.7, pp.345-494, 2001.

M. S. Sabatine, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, issue.12, pp.352-1179, 2005.

S. B. King, Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology, American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on, 2005.

S. Silber, Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology, ACC Current Journal Review, vol.14, issue.8, pp.26-804, 2005.
DOI : 10.1016/j.accreview.2005.08.063

H. Tran and S. S. Anand, Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease, JAMA, vol.292, issue.15, pp.292-1867, 2004.
DOI : 10.1001/jama.292.15.1867

K. L. Furie, Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke, vol.42, issue.1, pp.227-76
DOI : 10.1161/STR.0b013e3181f7d043

H. C. Diener, Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in highrisk patients (MATCH): randomised, double-blind, placebo-controlled trial, Lancet, issue.9431, pp.364-331, 2004.

V. Fuster, guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation), Eur Heart J, issue.16, pp.27-1979, 2006.

B. F. Gage, Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin, Circulation, vol.110, issue.16, pp.110-2287, 2004.
DOI : 10.1161/01.CIR.0000145172.55640.93

B. F. Gage, Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.285-2864, 2001.
DOI : 10.1001/jama.285.22.2864

R. O. Bonow, ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in Collaboration With the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons, Circulation, vol.114, issue.5, pp.48-49, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.176857

L. Ryden, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of, Diabetes

S. Acfediam, Recommandations sur la prise en charge du patient diabétique vu par le cardiologue, pp.35-39, 2004.

M. Sobel and R. Verhaeghe, Antithrombotic Therapy for Peripheral Artery Occlusive Disease, Chest, vol.133, issue.6, pp.815-843, 2008.
DOI : 10.1378/chest.08-0686

T. J. Kiernan, B. P. Yan, and M. R. Jaff, Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease, Journal of Vascular Surgery, vol.50, issue.2, pp.431-440, 2009.
DOI : 10.1016/j.jvs.2009.04.052

A. Halliday, Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial, Lancet, issue.9420, pp.363-1491, 2004.

L. Saba and G. Mallarini, A comparison between NASCET and ECST methods in the study of carotids, European Journal of Radiology, vol.76, issue.1, pp.42-49
DOI : 10.1016/j.ejrad.2009.04.064

P. M. Rothwell, Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis, Lancet, issue.9352, pp.361-107, 2003.

T. Reiff, Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis vs. Endarterectomy: SPACE2 ??? a Three-Arm Randomised-Controlled Clinical Trial, International Journal of Stroke, vol.20, issue.4, pp.294-303, 2009.
DOI : 10.1161/01.STR.0000199147.30016.74

G. Lanzino, A. A. Rabinstein, R. D. Brown, and J. , Treatment of carotid artery stenosis: medical therapy, surgery, or stenting? Mayo Clin Proc, pp.362-87, 2009.

T. F. Imperiale and A. S. Petrulis, A Meta-analysis of Low-Dose Aspirin for the Prevention of Pregnancy-Induced Hypertensive Disease, JAMA: The Journal of the American Medical Association, vol.266, issue.2, pp.260-264, 1991.
DOI : 10.1001/jama.1991.03470020086038

S. Miyakis, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006.
DOI : 10.1093/ajcp/103.1.103

M. Petri, Epidemiology of the Antiphospholipid Antibody Syndrome, Journal of Autoimmunity, vol.15, issue.2, pp.145-51, 2000.
DOI : 10.1006/jaut.2000.0409

D. Cohen, Diagnosis and management of the antiphospholipid syndrome, BMJ, vol.340, issue.may14 1, p.2541
DOI : 10.1136/bmj.c2541

G. Ruiz-irastorza, Antiphospholipid syndrome, The Lancet, vol.376, issue.9751, pp.1498-509
DOI : 10.1016/S0140-6736(10)60709-X

W. Lim, M. A. Crowther, and J. W. Eikelboom, Management of Antiphospholipid Antibody Syndrome, JAMA, vol.295, issue.9, pp.1050-1057, 2006.
DOI : 10.1001/jama.295.9.1050

M. Empson, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database of Systematic Reviews, vol.99, issue.1, p.2859, 2005.
DOI : 10.1016/S0015-0282(16)58565-3

L. Friberg, Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study), Eur Heart J, issue.16, pp.27-1954, 2006.

A. Gentric and S. Estivin, L'utilisation des??anticoagulants chez??le??sujet ??g??, La Revue de M??decine Interne, vol.27, issue.6, pp.458-64, 2006.
DOI : 10.1016/j.revmed.2005.10.006

E. Touze, Formes anévrismales de dissection des artères cervicales, pp.13-17, 2002.

S. Engelter, Dissection des artères nourricières du cerveau : anticoagulation ou inhibiteurs de l'agrégation plaquettaire? forum Med Suisse, pp.378-382, 2008.

B. Guillon, Dissections artérielles cervicales : modalités diagnostiques et thérapeutiques. MT Cardio, pp.364-373, 2005.

P. Déglise, Occlusion de la veine centrale de la rétine, 2002.

. Bibliomed, Quelle place pour l'aspirine en prévention primaire cardiovasculaire ?, 2006.

S. E. Kjeldsen, Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study, Journal of Hypertension, vol.18, issue.5, pp.629-671, 2000.
DOI : 10.1097/00004872-200018050-00017

A. Zanchetti, Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk, Journal of Hypertension, vol.20, issue.11, pp.20-2301, 2002.
DOI : 10.1097/00004872-200211000-00031

S. Acfediam, Recommandations sur la prise en charge du patient diabétique vu par le cardiologue, 2004.

C. Tribouilloy, Recommandations de la Société française de cardiologie concernant la prise en charge des valvulopathies acquises et des dysfonctions de prothèse valvulaire. Indications opératoires et interventionnelles, Arch Mal Coeur Vaiss, issue.2, p.98, 2005.

G. Jondeau, Recommandations sur la prise en charge médicamenteuse des atteintes aortiques du syndrome de Marfan, Arch Mal Coeur Vaiss, vol.99, issue.5, pp.540-546, 2006.

G. Jondeau, Insuffisance cardiaque et cardiomyopathies Arch Mal Coeur Vaiss, pp.51-52, 2006.

V. Annexes, Annexe 1 : lettre d'invitation à participer au premier tour de l, p.144